Shield Therapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan '26 Jan 29, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	133	26	60	21	114	83
Market Cap Growth	509.80%	-57.71%	192.87%	-81.97%	37.20%	-66.33%
Enterprise Value	146	37	53	18	87	76
Last Close Price	0.13	0.03	0.07	0.07	0.45	0.64
PS Ratio	3.75	0.82	5.10	4.01	63.24	7.19
PB Ratio	-10.48	-20.07	4.44	3.37	2.36	2.47
P/TBV Ratio	-	-	4.82	4.15	4.11	6.53
P/FCF Ratio	30.81	-	-	-	-	-
P/OCF Ratio	30.81	-	-	-	-	-
EV/Sales Ratio	4.18	1.19	4.50	3.48	48.36	6.56
EV/EBITDA Ratio	-	-	-	-	-	2840.59
EV/FCF Ratio	33.99	-	-	-	-	-
Debt / Equity Ratio	-1.82	-20.02	1.35	1.04	0.00	0.00
Debt / EBITDA Ratio	-	-	-	-	-	1.17
Debt / FCF Ratio	5.35	-	-	-	-	-
Asset Turnover	0.76	0.61	0.35	0.14	0.04	0.30
Inventory Turnover	3.98	3.89	3.65	1.63	0.65	1.16
Quick Ratio	0.69	0.90	1.83	0.62	3.73	1.60
Current Ratio	0.83	1.16	2.28	0.95	4.64	2.32
Return on Equity (ROE)	-	-396.36%	-308.60%	-179.19%	-55.46%	-8.43%
Return on Assets (ROA)	-16.77%	-26.90%	-51.93%	-49.37%	-32.97%	-3.91%
Return on Capital Employed (ROCE)	-120.80%	-92.00%	-89.40%	-229.50%	-49.90%	-7.10%
Earnings Yield	-13.64%	-102.83%	-49.88%	-225.97%	-20.48%	-3.52%
FCF Yield	3.25%	-25.74%	-55.98%	-102.82%	-19.40%	-1.87%
Buyback Yield / Dilution	-19.74%	-8.33%	-209.85%	-14.08%	-74.36%	-0.21%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.